BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 384,624 shares, a drop of 52.2% from the August 15th total of 804,376 shares. Based on an average daily trading volume, of 360,841 shares, the short-interest ratio is currently 1.1 days.

Large investors have recently bought and sold shares of the stock. Citadel Advisors LLC raised its position in BioLineRx by 443.4% during the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the period. Renaissance Technologies LLC acquired a new position in BioLineRx during the first quarter valued at $126,000. KCG Holdings Inc. raised its position in BioLineRx by 715.9% during the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC acquired a new position in BioLineRx during the first quarter valued at $3,018,000. 32.27% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have issued reports on BLRX shares. Zacks Investment Research lowered BioLineRx from a “buy” rating to a “sell” rating in a research note on Tuesday, June 20th. Maxim Group set a $3.00 price target on BioLineRx and gave the stock a “buy” rating in a research note on Monday, July 10th. Oppenheimer Holdings, Inc. started coverage on BioLineRx in a research note on Friday, August 4th. They issued an “outperform” rating and a $3.00 price target on the stock. ValuEngine raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Roth Capital started coverage on BioLineRx in a research note on Thursday, August 3rd. They issued a “buy” rating and a $3.00 price target on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $2.59.

Shares of BioLineRx (NASDAQ:BLRX) opened at 1.05 on Friday. The firm has a 50-day moving average price of $1.08 and a 200-day moving average price of $0.97. The firm’s market capitalization is $100.40 million. BioLineRx has a 52 week low of $0.80 and a 52 week high of $1.42.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). On average, equities analysts expect that BioLineRx will post ($0.24) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/16/biolinerx-ltd-blrx-short-interest-update.html.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.